Telluride Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Telluride Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	$448K	Buy	+2,870	New	+$453K	0.38%	95

Other funds holding ALXN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Telluride Asset Management's ALXN Position: Q2 2014 in Review

Telluride Asset Management opened a new position in Alexion Pharmaceuticals (ALXN) in Q2 2014: 2,870 shares worth $448K. The stake represents 0.38% of the portfolio and ranks #95 among its holdings.

521 funds tracked by Wall St. Rank hold ALXN as of Q2 2014.

Telluride Asset Management held 2,870 shares of Alexion Pharmaceuticals worth $448K as of Q2 2014.
Alexion Pharmaceuticals was a new Telluride Asset Management position in Q2 2014.
Alexion Pharmaceuticals made up 0.38% of Telluride Asset Management's portfolio in Q2 2014, its #95 holding.
521 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2014.

Based on Telluride Asset Management's 13F filing for Q2 2014, filed 14 Aug 2014.